Rohitash Yadav | Drug Discovery | Young Scientist Award

Dr. Rohitash Yadav | Drug Discovery | Young Scientist Award 

Assistant Professor at Pacific Medical College and Hospital, Udaipur, India

Dr. Rohitash Yadav is a highly accomplished researcher with expertise in pharmacology, computational biology, and drug design. Currently serving as an Assistant Professor at Pacific Medical College and Hospital, Udaipur, Dr. Yadav’s research focuses on finding innovative solutions for cancer treatment and infectious diseases. His extensive work on SARS-CoV-2 and multiple myeloma has earned him widespread recognition. Dr. Yadav has authored numerous high-impact scientific articles and has consistently been honored for his contributions to biomedical research.

Profile:

ORCID

Education:

Dr. Yadav holds a PhD from the All India Institute of Medical Sciences (AIIMS), Rishikesh, where he specialized in pharmacology and computational drug design. Prior to this, he earned a Master’s degree in Medical Pharmacology from the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh. His academic journey has equipped him with the necessary skills to lead cutting-edge research projects in both academia and healthcare.

Experience:

Dr. Yadav’s professional journey includes significant research and academic roles. He is currently an Assistant Professor at Pacific Medical College and Hospital, Udaipur. Before that, he served as a Junior Research Fellow at AIIMS Rishikesh, where he was instrumental in leading research initiatives aimed at drug discovery and the development of therapeutic strategies for multiple myeloma and viral diseases. His broad research collaborations span across global institutions, reflecting his leadership in the biomedical field.

Research Interests:

Dr. Yadav’s primary research areas include computational drug design, molecular docking, and in-silico and in-vitro pharmacological studies. He is deeply engaged in the study of potential inhibitors targeting various cancerous pathways, with a strong emphasis on multiple myeloma and COVID-19 therapies. His interdisciplinary approach, combining computational biology with clinical pharmacology, allows for the identification of novel therapeutic compounds and proteins that can be targeted to treat life-threatening diseases.

Awards:

Dr. Yadav has been the recipient of numerous prestigious awards throughout his academic career. His contributions to the biomedical field were recognized by the Best Researcher Award at AIIMS Rishikesh in 2022 and 2023. Additionally, he was awarded the Junior Research Fellowship from AIIMS Rishikesh between 2020-2022. His work on computational biology and drug design has earned him accolades from national and international conferences.

Publications:

Dr. Yadav has an impressive array of publications, including some of the most-cited works in the field. Key publications include:

Yadav R, Mathur I, et al. Dostarlimab: Review on success story and clinical trials. Critical Reviews in Oncology/Hematology (2024). doi:10.1016/j.critrevonc.2024.104374 – Cited by 12 articles.

Gupta SM, Jain NK, Yadav R, et al. Computational investigation of the interaction of novel indene methylene analogues with acetylcholinesterase. Letters in Drug Design & Discovery (2023). doi:10.2174/1570180819666220623144252 – Cited by 18 articles.

Yadav R, Nath UK, et al. Identification and in-vitro analysis of potential proteasome inhibitors for multiple myeloma. Biomedicine & Pharmacotherapy (2023). doi:10.1016/j.biopha.2022.113963 – Cited by 25 articles.

Yadav R, Hasan S, et al. Molecular docking, DFT analysis, and dynamics simulation of natural bioactive compounds targeting ACE2 and TMPRSS2 dual binding sites of spike protein of SARS CoV-2. Journal of Molecular Liquids (2021). doi:10.1016/j.molliq.2021.116942 – Cited by 34 articles.

Yadav R, Celik I, et al. Interactions of the receptor-binding domain of SARS-CoV-2 variants with hACE2: Insights from molecular docking analysis. Biology (2021). doi:10.3390/biology10090880 – Cited by 40 articles.

Yadav R, Kumar JK, et al. Host cell and SARS-CoV-2-associated molecular structures as potential therapeutic targets. Cells (2021). doi:10.3390/cells10092427 – Cited by 28 articles.

Yadav R, Celik I, et al. Investigation of reactive properties, adsorption on fullerene, DFT, molecular dynamics simulation of an anthracene derivative targeting dihydrofolate reductase and human dUTPase. Journal of Biomolecular Structure and Dynamics (2021). doi:10.1080/07391102.2021.1953602 -Cited by 20 articles.

Yadav R, Kumar JK, et al. Insights into COVID-19 vaccine development based on immunogenic structural proteins of SARS-CoV-2. Cells (2021). doi:10.3390/cells10112949 – Cited by 35 articles.

Conclusion:

Dr. Rohitash Yadav’s proven track record in high-impact research, coupled with his leadership in the scientific community and consistent recognition through awards, strongly support his candidacy for the Young Scientist Award. His innovative work in pharmacology, especially in computational drug design, and his proactive engagement with biomedical research make him a well-rounded candidate poised to make significant contributions in the future. However, further emphasis on interdisciplinary collaborations and public outreach could elevate his profile even higher.

Abdulfatai Ajiboye | medicinal Chemistry | Best Researcher Award

Dr. Abdulfatai Ajiboye | medicinal Chemistry | Best Researcher Award

Lecturer, Kwara State University, Malete, Nigeria

Dr. Ajiboye Abdulfatai Temitope is a distinguished scholar and lecturer in the Department of Chemistry and Industrial Chemistry at Kwara State University, Malete, Nigeria. With extensive experience in natural products and medicinal chemistry, Dr. Ajiboye has significantly contributed to the field through his research on bioactive compounds from natural sources. He has held various academic positions, fostering a strong commitment to teaching and community development. 🌟📚

Profile

Google Scholar

Education🎓

Dr. Ajiboye earned his Ph.D. in Chemistry, specializing in Natural Products/Medicinal Chemistry and Organic Chemistry, from the University of Lagos, Nigeria, in December 2021. He also holds an M.Sc. in Chemistry from the University of Ilorin (2014) and a B.Sc. (Honours) in Chemistry from the same institution (2007). 🎓🔬

Experience🏫

Dr. Ajiboye is currently a Lecturer I at Kwara State University, a role he has held since 2022. He previously served as Lecturer II (2017-2022) and Assistant Lecturer (2014-2017) at the same institution. His expertise includes molecular networking, virtual screening, and the design and synthesis of bioactive organic molecules. 🌐🧪

Research Interests📚

Dr. Ajiboye’s research focuses on isolating and characterizing bioactive compounds from natural sources, designing and synthesizing small organic molecules with biological properties, and employing molecular networking and virtual screening techniques to identify novel compounds. His work also includes studying the antioxidant, antimicrobial, and antihyperglycemic properties of phytochemicals. 🌿🔍

Awards🏆

Dr. Ajiboye has been recognized for his significant contributions to chemistry and medicinal plant research. He is a member of esteemed professional societies, including the Society for Medicinal Plants and Economic Development (SOMPED) and the American Society for Pharmacognosy (ASP). 🏆🏅

Publications

Extraction of Phenolic Compounds from Some Ayurvedic Botanicals and Evaluation of Their Antibacterial and Antiviral Properties Using Bioinformatics Approaches (2024). Computational Approaches in Biotechnology and Bioinformatics. Link 🌐

Phytochemicals and Enzymes Inhibitory Potentials Of Leaves and Root Barks of Sarcocephalus latifolius (Smith): In Vitro and in Silico Investigations (2024). SSRN. Link 📄

Physicochemical Analyses of Coconut (Cocos nucifera L.) Oil Obtained by Solvent (Aqueous and n-hexane) Extraction Methods (2024). International Journal of Research in Pharmacy and Allied Science (IJRPAS). 🌍

Synthesis, Characterization and α-amylase Inhibition Study of Substituted Schiff Base and its Metal Complexes (2023). IJRPAS. 📘

Epigenetic Oncogenesis, Biomarkers and Emerging Chemotherapeutics for Breast Cancer (2022). BBA-Gene Regulatory Mechanisms. Link 🔬